The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors
Clinical trial NCT06772610 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06772610
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-15
- Primary completion
- 2029-03-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.